NEW YORK (GenomeWeb) – Enzo Biochem reported after the close of the market on Thursday that its fourth quarter revenues rose 4 percent year over year, thanks to an increase in revenues from its clinical laboratory services business.

For the three-month period ended July 31, the molecular diagnostics company reported revenues of $26.6 million, up from $25.7 million a year earlier.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.